Stephen L. Eck, M.D., Ph.D.
Chief Medical Officer, Immatics
As Chief Medical Officer of Immatics US, Inc., Stephen Eck leads the clinical development of Immatics Adoptive Cell Therapy programs in Houston. Stephen Eck previously served as VP Oncology Medical Sciences at Astellas Pharma Global Development managing a portfolio of assets which included enzalutamide (Xtandi), erlotinib (Tarceva) and gilteritinib.
Stephen Eck is a hematologist and oncologist with more than twenty-five years of experience in academic and industrial biomedical research. He began his professional career at Monsanto in cancer target discovery and later joined the University of Pennsylvania, where he was the Anne B. Young Assistant Professor of Cancer Research and the Director of the Cancer Gene Therapy Program. He subsequently held leadership roles in drug development at Pfizer, as VP Translational Medicine and Molecular Profiling, and at Lilly, as VP Translational Medicine, Pharmacology and Pharmacogenomics prior to joining Astellas.
Stephen Eck has authored numerous publications in basic and clinical research and public policy. He is a fellow of the American Association for the Advancement of Science. He serves on the Board of Directors of Luminex Corporation (Austin, TX), on the Board of Directors of the Central Pennsylvania Clinic (Belleville, PA), and on the External Advisory Committee of the University of Pennsylvania Orphan Diseases Program (Philadelphia). He is also a trustee of the Keck Graduate Institute (Claremont, CA).
He received an B.A. (chemistry) from Kalamazoo College, an M.S. and a Ph.D. (chemistry) from Harvard University and an M.D. from the University of Mississippi with Residency (Internal Medicine) and Fellowship (Hematology & Oncology) training at the University of Michigan.
Jay G. Wohlgemuth, M.D.
Board Vice Chair
Chief Medical Officer, Senior Vice President, Quest Diagnostics
Jay G. Wohlgemuth, M.D., is Chief Medical Officer and Senior Vice President, Research & Development and Medical for Quest Diagnostics. Based at Quest Diagnostics Nichols Institute, in San Juan Capistrano, California, Dr. Wohlgemuth is responsible for Research & Development (R&D), Medical Affairs and Medical/Lab Quality. In addition, he is responsible for improving outcomes for employees who use Quest's health benefits.
Dr. Wohlgemuth has many years of experience in medical diagnostics and research and development. He rejoined Quest in 2016 from HealthTap, a health information start-up, where he served as Senior Vice President and Chief Healthcare Officer. Prior to that, he was Senior Vice President, R&D, Medical and Chief Scientific Officer with Quest. Dr. Wohlgemuth originally joined Quest in 2009 from Genentech, where he was Director, Clinical Diagnostics, ITGR (Immunology, Tissue Growth and Repair) and Global Development Team Leader for Ocrulizumab. He also served as Vice President, Research and Development for VIA Pharmaceuticals and as Chief Medical Officer for the molecular diagnostics company XDx, a company he co-founded. In addition, Dr. Wohlgemuth served as Vice President, Research & Development for XDx. For his work at XDx he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos. He serves on the Board of Directors for the Diagnostic Labs of Oklahoma and The Anne and Henry Zarrow Charitable Foundation.
Dr. Wohlgemuth earned his bachelor’s degree in biology from Harvard College and his medical degree from Stanford University School of Medicine, where he also served a fellowship in cardiovascular medicine.
Peter Maag, Ph.D.
CEO, President, CareDx
Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Dr. Maag was President of Novartis Diagnostics based in Emeryville, California. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis' headquarters in Switzerland, he helped launch the Infectious Diseases franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various health care and high tech companies in their growth efforts, he holds board and advisory positions at Phoenix, MolecularMD and the Personalized Medicine Coalition. Dr. Maag studied pharmaceutical sciences in Heidelberg and London, and received his Ph.D. from the University of Berlin, Germany.
Bonnie J. Addario
Founder, Chair & Lung Cancer Survivor, Bonnie J. Addario Lung Cancer Foundation
Bonnie has been an activist, advocate, educator and change agent empowering patients and giving them a strong voice in the fight against lung cancer since receiving a stage 3B diagnosis more than a decade ago. Although thrust into a role that she had never envisioned for herself, she embraced it and now considers it to be her second career and a personal calling. Recognizing the critical need for education, empowerment, advocacy and research to help patients and families, especially those without resources and support, Bonnie and her family founded the Bonnie J. Addario Lung Cancer Foundation (ALCF) in 2006, and then went on to found the Addario Lung Cancer Medical Institute (ALCMI) with her husband, Tony Addario, in 2008. Bonnie’s business acumen and skills honed in her first career as President of Olympian Oil Company and Commercial Fueling Network (CFN), as Past President of the CA Independent Oil Marketers Association (CIOMA) and as a community activist serving on diverse boards have all contributed to her work at ALCF in developing business strategies and being the Foundation’s patient voice at national/international conferences, on panels and boards, and to industry leaders, clinicians and policy makers. Bonnie’s personal interests include collecting wine, travel, sports (Go SF Giants!) and spending time with family and friends at Lake Tahoe.
Steven D. Averbuch, M.D.
Vice President, Head of Precision Medicine, Bristol-Myers Squibb
Dr. Averbuch is Vice President and Head, Precision Medicine within the Translational Medicine Division of R&D at Bristol-Myers Squibb. In this role, Steve leads integrated biomarker and pharmacodiagnostic activities across the BMS R&D portfolio.
Dr. Averbuch joined Bristol-Myers Squibb in 2006, and he has led the Pharmacodiagnostics Center of Excellence since 2008. Other previous roles included: leading the strategy, business development agreements and execution of external clinical collaborations for the company’s immuno-oncology pipeline; executive sponsor and oversight for translational research activities for all late development and marketed oncology compounds; leader of corporate-wide strategic initiatives for translational and targeted medicine; co-leader of the oncology early strategy team and that included responsibility for the execution of Phase 2 oncology programs. Dr. Averbuch has made significant contributions to business development and he has participated in multiple successful licensing and acquisition deals.
Dr. Averbuch previously held positions at Merck Research Laboratories, AstraZeneca and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.
Averbuch has authored over sixty peer reviewed publications and book chapters,
and he is a co-author on one patent. He
is currently on the Steering Committee of the National Biomarker Development
Alliance and the Advisory Board for the University of Kansas Institute for
Advancing Medical Innovation. He is also a member of the American Society of
Clinical Oncology and the American Association for Cancer Research having
served on multiple committees for both organizations. Dr. Averbuch is the 2014 recipient of the
University of Illinois College of Medicine Distinguished Alumnus Award.
Vice President, Policy and Research, PhRMA
Randy Burkholder is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Burkholder directs PhRMA work on issues related to use of evidence in healthcare decision-making, health technology assessment, comparative and costeffectiveness research, Medicare coverage policy, innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies, including the Medicare Evidence Development and Coverage Advisory Committee, the Federal Coordinating Council for Comparative Effectiveness Research, Institute of Medicine Committees and President’s Council of Advisors on Science and Technology. He also is a founding member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care.
Mr. Burkholder has over 17 years of experience in healthcare policy, advocacy and
communications in the medical technology and pharmaceutical industries. Prior to
joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at
AdvaMed, the leading association of the medical device and diagnostics industries.
William S. Dalton, Ph.D., M.D.
Founder, Executive Chairman, M2Gen
Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Dr. William “Bill” S. Dalton is the Founder and Executive Chairman of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to his role as the President, CEO & Center Director of Moffitt Cancer Center, Dr. Dalton was the Dean of the University of Arizona College of Medicine.
Dr. Dalton is interested in the development of personalized cancer care and patient-centered outcomes research through Moffitt’s nationally renowned Total Cancer CareTM approach to developing evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care includes one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated to the development of personalized medicine. He is also recognized as a founder of ORIEN, an alliance of cancer centers who have agreed to use the Total Cancer Care protocol to generate and share data for collaborative research and learning. For his leadership in this area, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and personalized medicine.
President, CEO, NanoString Technologies
R. Bradley Gray has served as a member of NanoString's board of directors and as President & Chief Executive Officer since June 2010. Prior to joining the company, Mr. Gray held various positions at Genzyme, a biotechnology company acquired by Sanofi in 2011. He served as Vice President of Product & Business Development for Genzyme Genetics, the diagnostic services division of Genzyme, from June 2008 to May 2010, leading the development of molecular diagnostics and partnering activities. From September 2006 to June 2008, he served as Vice President of Business & Strategic Development for Genzyme Genetics, leading growth efforts through partnerships and licensing. Mr. Gray joined Genzyme in October 2004 as Director of Corporate Development, supporting business development and leading Genzyme Ventures, the corporate venture capital fund of Genzyme. Prior to joining Genzyme, Mr. Gray was a management consultant in the health care practice of McKinsey & Company, a global management consulting firm, from September 2000 to October 2004, where he worked with senior health care executives in the United States and Europe on a broad range of issues including pharmaceutical and diagnostic product strategy, post-merger integration, organization design and operational turnarounds. Mr. Gray received a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.
Kris Joshi, Ph.D.
Executive Vice President, President, Network Solutions, Change Healthcare
Mr. Joshi is Executive Vice President and President, Network Solutions for Change Healthcare. He initially joined Change Healthcare as Executive Vice President, Products in December 2013. Prior to that, Mr. Joshi was Global Vice President for health care product strategy for the Health Sciences Global Business Unit of the Oracle Corporation. He helped launch the health sciences business unit and successfully led two acquisitions for Oracle in the life sciences space. Before joining Oracle, Mr. Joshi served in senior strategy roles in IBM’s Global Sales and Distribution organization. Prior to that, Mr. Joshi was with McKinsey and Company, where he served Fortune 500 clients on strategy issues.
Mr. Joshi holds a Bachelor's degree in mathematics from Caltech, and a Ph.D. in physics from MIT.
Senior Vice President, Global Head of Precision Medicine, Novartis
Anne-Marie Martin is SVP, Global Head of Precision Medicine in the Global Drug Development organization. In this position, she is responsible for designing and implementing an end-to-end Precision Medicine Strategy to support the Novartis pipeline, encompassing biomarker discovery and development including the development of companion diagnostic assays. Dr. Martin leads a cross-functional team, including members from the discovery, regulatory and commercial organizations, and she collaborates with the Early Commercial Strategy and Market Access Teams to drive and implement early diagnostic strategies in support of Novartis’ medicines.
After some years in academia and hospital diagnostics in the University of Pennsylvania Health System, Dr. Martin joined the pharmaceutical industry and held different positions of increasing responsibilities in oncology translational research, clinical biomarkers and diagnostic development. Dr. Martin spent over ten years at GlaxoSmithKline, where she led a global team responsible for the precision medicine strategy in oncology to deliver all translational research into pipeline opportunities, accounting for over ten clinical assets and an additional five assets in the first-in-human setting, and she led the development of the companion diagnostic assay that supported the approvals of Tafinlar® and Mekinist™. During her tenure at GSK, Dr. Martin contributed to three NDAs and five sNDAs. Prior to joining NVS, Dr. Martin held the position of VP, Head of Biomarker Research and Development at Adaptimmune, LLC, which is a Philadelphia-based biotechnology company focussing on development of autologous TCRs.
Since joining Novartis in 2016, Dr. Martin has led the successful
approval of companion diagnostics in support of Rydapt® for Flt3 positive AML, ZykadiaTM
for ALK positive NSCLC and Tafinlar® and Mekinist™ for BRAF positive NSCLC.
Founder, Publisher, Genome magazine
Susan brings 29 years of journalistic experience to her role as Publisher for Genome magazine — the first consumer magazine exclusively devoted to personalized medicine and genomics. With over 300,000 copies distributed across the U.S. each quarter, Genome covers the personalized medicine stories of today and the breakthroughs of tomorrow, so that patients have the information they need to get the targeted treatments they deserve. Prior to its launch, she spent 10 years as the publisher of CURE — a magazine for cancer patients, survivors and caregivers. During her tenure at CURE, she also served as Vice President of Patient Engagement for McKesson Specialty Health. In 2016, Susan was honored by Folio as one of the “Top Women in Media” for her entrepreneurial efforts in magazine publishing and media. She has over 20 years of experience delivering first-class sales and management strategies to leading and start-up media and health care organizations, and is especially skilled at creating collaborative partnerships that result in highly respected educational offerings for patients and health care providers.
Howard McLeod, Pharm.D.
Medical Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Dr. Howard McLeod is the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He is also a Senior Member of the Division of Population Sciences. Most recently, he was the Fred Eshelman Distinguished Professor and Founding Director of the UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill. Dr. McLeod held appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Comprehensive Cancer Center.
Dr. McLeod is also chair of the NHGRI eMERGE network external scientific panel and a recent member of the FDA committee on Clinical Pharmacology and the NIH NHGRI Advisory Council. Since 2002, Dr McLeod has been vice chair for Pharmacogenomics for the NCI clinical trials cooperative group CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is also a 1000 talent scholar of China and a professor at Central South University in Changsha, China. He directs the Pharmacogenetics for Every Nation Initiative, which aims to help developing countries use genetic information to improve National Drug Formulary decisions.
Dr. McLeod has also been an active entrepreneur, serving on the Board of Directors, Scientific Advisory Board, and as a domain expert consultant to for-profit companies. He has founded both for-profit and non-profit companies in the USA and China. Howard has published more than 475 peer reviewed papers on pharmacogenomics, applied therapeutics or clinical pharmacology and continues to work to integrate genetics principles into clinical practice to advance individualized medicine.
J. Brian Munroe
Vice President, Government Affairs, Bausch Health Companies Inc.
Brian Munroe is the founder and Past-President of the Personalized Medicine Coalition (PMC). He currently serves as the Chairman of PMC's Public Policy Committee and on the Executive Committee of PMC's Board of Directors.
A twenty-five year veteran of health care public policy, advocacy, and communications, Brian's areas of expertise include FDA legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine. As Chairman of the Public Policy Committee, he oversees PMC's public policy initiatives and its interactions with the federal government.
Brian has created successful, stand alone Government Affairs Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo Pharmaceuticals. He is currently Vice President, Government Affairs at Bausch Health Companies.
Lincoln Nadauld, M.D., Ph.D.
Executive Director, Precision Medicine and Precision Genomics, Intermountain Healthcare
Dr. Nadauld is Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare, an integrated healthcare system, where he oversees the clinical implementation of precision medicine across 22 hospitals and 180 physician clinics.
Dr. Nadauld is a Visiting Scholar at Stanford University School of Medicine in the Division of Oncology, focusing on cancer genomics and personalized cancer medicine. His work has been published in journals such as Nature Medicine, Journal of Clinical Oncology, and Genome Medicine. Dr. Nadauld serves as an Associate Editor for the Journal of Clinical Oncology-Precision Oncology. He also serves on the board of directors of the Gastric Cancer Foundation and reviews grant applications on behalf of the US Department of Defense.
Dr. Nadauld received a bachelor of science degree from Brigham Young University and a combined medical degree/Ph.D. from the University of Utah. He completed clinical training in medical oncology at Stanford University School of Medicine, where he also completed a postdoctoral fellowship in solid tumor genomics.
Michael J. Pellini, M.D., M.B.A.
Managing Partner, Section 32
Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017.
He currently serves as a member of the Board of
Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies
and the Mission Hospital Foundation. As a physician with more than twenty years of
executive experience with companies at the forefront of clinical diagnostics
and genomics, Dr. Pellini brings a breadth of understanding in personalized
medicine, with a particular interest and focus on defeating cancer. Dr. Pellini
is a member of the President’s Leadership Council at Thomas Jefferson
University and Jefferson Health, as well as the Advisory Board for Mission
Hospital’s Cancer Institute (Provident/St. Joseph Health).
Dr. Pellini received a B.A. from Boston College, an M.B.A. from Drexel University and an M.D. from Jefferson Medical College.
Chairman of the Board, CEO, President, Genomic Health
Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the over-treatment and optimal treatment of early-stage cancer, one of the greatest issues in health care today.
Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the American Clinical Laboratory Association (ACLA), and MyoKardia. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Adviser to the Healthcare Businesswomen’s Association (HBA).
Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by the Women Health Care Executives.
Kim holds a Bachelor of Arts degree in Business from Michigan State University.
Hakan Sakul, Ph.D.
Vice President, Head of Diagnostics, Worldwide R & D, Pfizer Inc.
Hakan leads Pfizer’s Companion Diagnostics efforts across the Worldwide R&D organization and is also responsible for Pfizer’s internal Biobank group. His formal education includes BS (1983) and MS (1984) degrees from Ankara University in Turkey, PhD (1990) in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar, and postdoctoral studies in genetics at the University of California-Davis (1990-94).
Hakan worked in the biotech industry in human genetics and statistical genetics fields across multiple disease areas before moving to Parke-Davis Pharmaceuticals in 1998 to direct human genetics, statistical genetics and pharmacogenetics programs. Following the merger of Warner-Lambert/Parke-Davis with Pfizer, he has held positions of increasing responsibility in Clinical Pharmacogenomics, Molecular Profiling, and Translational Oncology. Hakan interacted closely with Pfizer’s Executive Leadership Team and the Board of Directors to define and implement Pfizer’s current companion diagnostics strategy. One of his most significant professional accomplishments was to lead the companion diagnostics program for Xalkori® (Crizotinib), Pfizer’s flagship program in companion diagnostics. Hakan served on the clinical development and drug/diagnostics submission teams and led the companion diagnostics program to a successful delivery, resulting in simultaneous FDA approvals of both the drug and the companion diagnostic test in 2011.
Hakan was then promoted to his current role to provide companion diagnostics leadership across Pfizer’s pharmaceutical pipeline. He led the internal efforts that resulted in companion diagnostics partnerships with Dako/Agilent and Siemens Healthcare Diagnostics, among others. Hakan’s contributions to precision medicine and companion diagnostics have been widely recognized through both internal and external awards, frequent speaking engagements, and press coverage. He is the author of over 30 referred scientific articles as well as many other papers, abstracts and book chapters.
Hakan is keenly interested in technologies for identification of patient sub-groups for targeted treatments and development of companion diagnostics to advance Precision Medicine for the improvement of individualized health care. He is an active member of civic clubs, and enjoys cycling, soccer, and stand-up paddle-boarding.
Michael Sherman, M.D., M.B.A., M.S.
Senior Vice President, Chief Medical Officer, Harvard Pilgrim Health Care
Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care. He works with physicians and health care organizations to achieve sustainable improvements in cost and quality. He has focused the organization on introducing innovative, outcomes-based reimbursement models and developing outcomes-based payment agreements. Dr. Sherman is the chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and also serves on the Advisory Board of the Institute for Clinical and Economic Review (ICER), the Board of Directors and as co-President of the Harvard Business School Healthcare Alumni Association, the Board of Advisors for the Harvard Business School Healthcare Initiative, and Board of Overseers for Boston’s Museum of Science.
Prior to joining Harvard Pilgrim, Dr. Sherman served as Corporate Medical Director, Physician Strategies, for Humana and held several leadership positions with UnitedHealth Group, Thomson Medstat (now IBM Truven), HealthAllies and Immusol.
Dr. Sherman holds a B.A. in anthropology and natural sciences and an M.S. in biomedical anthropology from the University of Pennsylvania. He received his M.D. from Yale and an M.B.A. from the Harvard Business School.
Sean Tunis, M.D., M.Sc.
Founder and Chief Executive Officer, Center for Medical Technology Policy
Sean Tunis, M.D., M.Sc. is the Founder and Chief Executive Officer of the Center for Medical Technology Policy in Baltimore, Maryland. CMTP’s main objective is to improve the quality and relevance of clinical research by providing a neutral forum for collaboration among experts, stakeholders and decision makers. Dr. Tunis was a member of the Institute of Medicine Committee on Initial National Priorities for Comparative Effectiveness Research. He advises a wide range of domestic and international public and private health care organizations on issues of comparative effectiveness, evidence based medicine, clinical research, reimbursement and health technology policy.
Through September of 2005, Dr. Tunis was the Director of the Office of Clinical Standards and Quality and Chief Medical Officer at the Centers for Medicare and Medicaid Services (CMS). In this role, he had lead responsibility for clinical policy and quality for the Medicare and Medicaid programs, which provide health coverage to over 100 million US citizens. Dr. Tunis supervised the development of national coverage policies, quality standards for Medicare and Medicaid providers; quality measurement and public reporting initiatives, and the Quality Improvement Organization program. As Chief Medical Officer, Dr. Tunis served as the senior advisor to the CMS Administrator on clinical and scientific policy. He also co-chaired the CMS Council on Technology and Innovation.
Dr. Tunis joined CMS in 2000 as the Director of the Coverage and Analysis Group. Before joining CMS, Dr. Tunis was a senior research scientist with the Technology Assessment Group, where his focus was on the design and implementation of prospective comparative effectiveness trials and clinical registries. Dr. Tunis also served as the Director of the Health Program at the Congressional Office of Technology Assessment and as a health policy advisor to the U.S. Senate Committee on Labor and Human Resources, where he participated in policy development regarding pharmaceutical and device regulation.
He received a B.S. degree in biology and history of science from the Cornell University School of Agriculture, and a medical degree and masters in health services research from the Stanford University School of Medicine. Dr. Tunis did his residency training at UCLA and the University of Maryland in Emergency Medicine and Internal Medicine. He is board-certified in Internal Medicine and holds adjunct faculty appointments at Johns Hopkins, Stanford and the University of California San Francisco Schools of Medicine.
Global Head, Janssen Diagnostics
Werner Verbiest is Global Head of Janssen Diagnostics, which was formed from the legacy organizations Virco (Infectious Diseases), Veridex (Oncology) and the Johnson & Johnson Companion Diagnostics Center of Excellence. Janssen Diagnostics focuses on personalized medicine within Janssen, incorporating therapeutic, diagnostic and real world data/health information technology solutions to improve patient outcomes.
Werner joined the Johnson & Johnson Family of Companies in 2002 following the acquisition of Tibotec-Virco. Before joining, he was active since 1992 in HIV drug development and hepatitis B therapeutic vaccine development in the International Clinical Research & Development group of the Janssen Research Foundation. He was one of the first employees of Virco in 1997 and had an instrumental role in Virco’s growth as Project and Business Development Director (1998), Managing Director (Virco Ireland, Ltd, 1999), Vice President of New Products Marketing and Pharma Business (2001) and General Manager from 2004 until its integration into Janssen Diagnostics.
Werner has been continually active in all phases of HIV clinical trial strategy and implementation, biomarker development (collaborative surrogate marker validation working groups with the United States Food and Drug Administration and the European Medicines Agency), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.
In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach both within and outside of Johnson & Johnson, including several board seats in different precision medicine and diagnostic organizations, including the European Personalised Medicine Association (EPEMED) and AdvaMedDx.